Truist Financial Increases ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $62.00

ANI Pharmaceuticals (NASDAQ:ANIP) had its price objective boosted by Truist Financial from $60.00 to $62.00 in a research note published on Tuesday, Benzinga reports. They currently have a hold rating on the specialty pharmaceutical company’s stock.

Several other brokerages have also commented on ANIP. Piper Sandler began coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target on the stock. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Tuesday, September 17th. Finally, Raymond James boosted their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.33.

ANI Pharmaceuticals Stock Performance

ANIP opened at $59.28 on Tuesday. The stock has a market cap of $1.24 billion, a PE ratio of 37.05 and a beta of 0.71. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals has a 1 year low of $48.20 and a 1 year high of $70.81. The stock’s 50 day simple moving average is $59.47 and its 200-day simple moving average is $62.17.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.07. The business had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $129.09 million. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. ANI Pharmaceuticals’s quarterly revenue was up 18.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.06 earnings per share. Sell-side analysts forecast that ANI Pharmaceuticals will post 3.58 EPS for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC boosted its stake in ANI Pharmaceuticals by 287.8% in the first quarter. Allspring Global Investments Holdings LLC now owns 21,277 shares of the specialty pharmaceutical company’s stock worth $1,471,000 after purchasing an additional 15,790 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in ANI Pharmaceuticals by 106.9% in the first quarter. BNP Paribas Financial Markets now owns 20,739 shares of the specialty pharmaceutical company’s stock worth $1,434,000 after purchasing an additional 10,716 shares in the last quarter. Wakefield Asset Management LLLP acquired a new position in ANI Pharmaceuticals in the first quarter worth $979,000. Sequoia Financial Advisors LLC acquired a new position in ANI Pharmaceuticals in the second quarter worth $600,000. Finally, Lisanti Capital Growth LLC acquired a new position in ANI Pharmaceuticals in the first quarter worth $2,218,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.